ArticleThoracic cancer2024
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Open access · goldAbstract read
In one paragraph
Article in Thoracic cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 3 pooled it
3.7field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 13 citations in OpenAlex.
- The optimal duration of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer: a systematic review of clinical trials.BMC pulmonary medicine · 2026Pooled it
- Immunotherapy rechallenge in metastatic renal cell carcinoma: a meta-analysis of randomized clinical trials.The oncologist · 2026Pooled it
- Efficacy and safety of two-year fixed versus continuous immune checkpoint inhibitor therapy in advanced or metastatic non-small cell lung cancer: a systematic review.Cancer immunology, immunotherapy : CII · 2025Pooled it
- Rechallenge with Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma: A Narrative Review.Liver cancer · 2026Review
- Comparing immunotherapy re-challenge plus chemoradiotherapy versus chemoradiotherapy alone in metastatic esophageal squamous cell carcinoma after first-line immunotherapy failure.Discover oncology · 2026Article
- Article
- Immune checkpoint inhibitor rechallenge in advanced NSCLC: prognostic value of the neutrophil-to-lymphocyte ratio.Translational lung cancer research · 2026Article
- Efficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or metastatic nasopharyngeal carcinoma: a real-world study.Cancer immunology, immunotherapy : CII · 2026Article
- Immune checkpoint inhibitor-associated diabetic ketoacidosis induced by cadonilimab: a case report and literature review.Frontiers in endocrinology · 2026Review
- Real-World Outcomes and Safety of PD-1 Blockade Rechallenge Strategies After Prior Immunotherapy in Advanced NSCLC: A Retrospective Cohort Study.Drug design, development and therapy · 2026Article
- Immunotherapy rechallenge in gastric cancer: resistance mechanisms, molecular stratification, and precision decision-making.Frontiers in immunology · 2026Review
- Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy.Cancer biology & medicine · 2025Article
- Efficacy and Safety of Second-Line Immune Checkpoint Inhibitor Rechallenge in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study.Thoracic cancer · 2025Article
- Efficacy and safety of immune checkpoint inhibitor rechallenge therapy in the treatment of advanced acquired immune-resistant non-small cell lung cancer: a retrospective study.Frontiers in oncology · 2025Article
- Effectiveness and Safety of Anlotinib-Related Therapeutic Regimens in Patients with Previously Immune Checkpoint Inhibitors-Treated Advanced NSCLC: A Real-World Exploratory Study.Drug design, development and therapy · 2025Article
- Continuation of same programmed death-1 inhibitor regime beyond progression is a novel option for advanced gastric cancer.BMC cancer · 2024Article
- Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.Thoracic cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
106 authors at 20 institutions in 3 countries.
Gen LinDepartment of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.ORCID 0000-0001-6793-552X
Zhijie WangDepartment of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Qian ChuDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yi HuSenior Department of Oncology, Chinese PLA General Hospital, Beijing, China.ORCID 0000-0001-9319-5692
Dingzhi HuangDepartment of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.ORCID 0000-0002-2798-9459
Jun WangDepartment of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Ji'nan, China.ORCID 0000-0003-3941-2507
Fan YangDepartment of Thoracic Surgery, Peking University People's Hospital, Beijing, China.
Wenzhao ZhongGuangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.ORCID 0000-0002-8917-8635
Chengzhi ZhouPulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.ORCID 0000-0003-0029-6879
Bo ZhuInstitute of Cancer, Xinqiao Hospital, Army Medical University, Chongqing, China.
Xinghao AiShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Baoshan CaoDepartment of Medical Oncology and Radiation Sickness, Cancer Center, Peking University Third Hospital, Beijing, China.
Yabing CaoDepartment of oncology, Kiang Wu Hospital, Macau, China.
Mingqiu ChenDepartment of Thoracic Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Xiaohui ChenDepartment of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Tianqing ChuRespiratory Department, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jianchun DuanDepartment of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID 0000-0003-1479-2304
Yun FanDepartment of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
Yong FangDepartment of Medical Oncology, Sir Run Run Shaw Hospital, Zhenjiang University School of Medicine, Hangzhou, China.
Shuitu FengDepartment of Medical Oncology, Fudan University Shanghai Cancer Center Xiamen Hospital, Xiamen, China.
Weineng FengDepartment of Pulmonary Oncology, The First People's Hospital of Foshan, Foshan, China.
Hui GuoDepartment of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Chengbo HanDepartment of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.ORCID 0000-0001-8391-6134
Yong HeDepartment of Respiratory Medicine, Xinqiao Hospital, Army Medical University, Chongqing, China.ORCID 0000-0002-9404-798X
Shaodong HongState Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer Center, Guangzhou, China.
Jie HuShanghai Geriatric Center, Zhongshan Hospital, Fudan University, Shanghai, China.
Meijuan HuangDivision of Thoracic Tumor Multimodality Treatment and Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.ORCID 0000-0002-3390-9697
Yan HuangState Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer Center, Guangzhou, China.
Da JiangDepartment of Oncology, The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, China.
Kan JiangDepartment of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Richeng JiangDepartment of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Bo JinDepartment of Medical Oncology, The First affiliated hospital of China Medical University, Shenyang, China.
Shi JinNational Cancer Center/National Clinical Research Cencer for Cancer/Cancer Hospital &Shenzhen Hospital, Chinese Academy of Medical Sciences and Perking Union Medical College, Shenzhen, China.ORCID 0000-0002-4462-2931
Jisheng LiDepartment of Medical Oncology, Qilu Hospital of Shandong University, Ji'nan, China.ORCID 0000-0002-4186-6228
Min LiDepartment of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, China.
Ziming LiShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chao LiDepartment of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Jie LinDepartment of Medical Oncology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.
Anwen LiuDepartment of Medical Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Si-Yang Maggie LiuDepartment of Hematology, First Affiliated Hospital, Ji'nan University, Guangzhou, China.
Liu YutaoDepartment of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhefeng LiuSenior Department of Oncology, Chinese PLA General Hospital, Beijing, China.
Zhe LiuDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Zhenhua LiuDepartment of Oncology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, China.
Zhentian LiuDepartment of Thoracic Oncology, Jiangxi Cancer Hospital, Nanchang, China.
Zhigang LiuCancer Center, The 10th Affiliated Hospital of Southern Medical University, Dongguan, China.
Yuping LuDepartment of Abdominal Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Tangfeng LvDepartment of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.ORCID 0000-0001-7224-8468
Zhiyong MaDepartment of Respiratory Medicine, Henan cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Qian MiaoDepartment of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Min PengCancer cenrter, Renmin Hospital of Wuhan University, Wuhan, China.ORCID 0000-0001-6648-945X
Xingxiang PuDepartment of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Xiu Bao RenDepartment of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Jianzhen ShanDepartment of Medical Oncology, The First Affiliated Hospital of Zhejiang University, Zhejiang, China.
Jinlu ShanDepartment of Medical Oncology, Daping Hospital, Army Medical University, Chongqing, China.
Peng ShenDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Bo ShenDepartment of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research and Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.ORCID 0000-0001-5709-5213
Meiqi ShiDepartment of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research and Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Yong SongDepartment of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.ORCID 0000-0003-4979-4131
Zhengbo SongDepartment of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou, China.
ChunXia SuDepartment of Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
Jianguo SunInstitute of Cancer, Xinqiao Hospital, Army Medical University, Chongqing, China.
Panwen TianPrecision Medicine Key Laboratory of Sichuan Province, Department of Pulmonary and Critical Care Medicine, Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China.ORCID 0000-0002-6313-3228
Jinliang WangSenior Department of Oncology, Chinese PLA General Hospital, Beijing, China.
Feng WangDepartment of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Huijuan WangDepartment of Respiratory Medicine, Henan cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Jialei WangDepartment of Thoracic Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Qian WangDepartment of Respiratory Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.
Wenxian WangDepartment of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.ORCID 0000-0002-3047-4149
Yan WangDepartment of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID 0000-0002-1743-6383
Lin WuDepartment of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Fang WuDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.ORCID 0000-0002-6627-3437
Yang XiaDepartment of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.ORCID 0000-0003-2487-2244
Congying XieDepartment of Radiation and Medical Oncology, Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.ORCID 0000-0002-1693-9034
Conghua XieDepartment of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.ORCID 0000-0001-6623-9864
Tao XinDepartment of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Jianping XiongDepartment of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Haipeng XuDepartment of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Song XuDepartment of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.ORCID 0000-0001-6153-387X
Yiquan XuDepartment of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Bin XuCancer cenrter, Renmin Hospital of Wuhan University, Wuhan, China.
Chunwei XuDepartment of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.ORCID 0000-0002-9021-6731
Xiaolong YanDepartment of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, China.
Zhenzhou YangDepartment of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Wenxiu YaoDepartment of Medical Oncology, Sichuan Cancer Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Yao YuDepartment of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Ye FengDepartment of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Zongyang YuDepartment of Respiratory Medicine, The 900th Hospital of the Joint Logistic Support Force, People's Liberation Army of China, Fuzhou, China.
Yongfeng YuShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Dongsheng YueDepartment of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Haibo ZhangDepartment of Oncology, Guangdong Provicial Hospital of Chinese Medicine, Guangzhou, China.
HongMei ZhangDepartment of Clinical Oncology, Xijing Hospital, Air Force Medical University, Xi'an, China.
Li ZhangDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Longfeng ZhangDepartment of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Qiuyu ZhangInstitute of Immunotherapy, Fujian Medical University, Fuzhou, China.
Tongmei ZhangDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, China.ORCID 0000-0003-4271-3773
Bicheng ZhangCancer cenrter, Renmin Hospital of Wuhan University, Wuhan, China.
Jun ZhaoKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department I of Thoracic Oncology, Peking University Cancer Hospital and Institute, Beijing, China.ORCID 0000-0003-1464-7158
Mingfang ZhaoDepartment of Medical Oncology, The First affiliated hospital of China Medical University, Shenyang, China.
Xiaobin ZhengDepartment of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Qiaofeng ZhongDepartment of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Jin ZhouDepartment of Medical Oncology, Sichuan Cancer Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Penghui ZhouState Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer Center, Guangzhou, China.
Zhengfei ZhuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Juntao ZouDepartment of Respiratory Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Zihua ZouDepartment of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.ORCID 0000-0003-0677-3998
Fujian Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNShanghai Jiao Tong University · CNCentral South University · CNChinese PLA General Hospital · CNTianjin Medical University Cancer Institute and Hospital · CNArmy Medical University · CNNanchang University · CNNanjing General Hospital of Nanjing Military Command · CNPeking University · CNSun Yat-sen University · CNWuhan University · CNZhejiang Cancer Hospital · CNFirst Affiliated Hospital of Guangzhou Medical University · CNFirst Hospital of China Medical University · CNFudan University Shanghai Cancer Center · CNGuangzhou University of Chinese Medicine · CNJiangsu Cancer Hospital · CNSichuan University · CNUniversity of Electronic Science and Technology of China · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitor (ICI) rechallenge in non-small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge can be divided into three categories: adverse events (AEs); resistance to ICIs, and rechallenge becomes compulsive because of tumor relapse while the patients had completed a 2 year course of immunotherapy. However, these categories are still controversial and should be explored further. Through voting at the 6th Straits Summit Forum on Lung Cancer, in this study we summarize the consensus of 147 experts in ICI rechallenges. A total of 97.74% experts agreed to rechallenge; 48.87% experts rechallenge with the original drug, and the others rechallenge with a different drug; 40.3% agreed to rechallenge directly after progression; 88.06% experts agreed to ICI rechallenge with a combination regimen; and factors such as previous performance status score, PD-1 expression, and age should also be considered. Understanding the the clinical studies in ICI rechallenge could bring us one step closer to understanding the consensus. In patients with advanced NSCLC who have suffered recurrent or distant metastasis after immunotherapy, the option of rechallenge with ICIs is a promising treatment option.
Indexed as
Carcinoma, Non-Small-Cell LungLung NeoplasmsConsensusHumansImmune Checkpoint InhibitorsImmunotherapyImmune Checkpoint InhibitorsICINSCLCre-challenge
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.